💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Cefonicid

CHEMBL1601 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
542.6 g/mol
LogP
-1.9
Phase
4

A prolonged half-life is the distinguishing pharmacokinetic feature of cefonicid among second-generation cephalosporins, permitting once-daily intramuscular administration where related agents require more frequent dosing. Antibacterial action follows the class mechanism: binding to penicillin-binding proteins arrests the final transpeptidation step of peptidoglycan assembly, leaving the wall defective and the organism osmotically unstable until lysis occurs. Coverage extends across many gram-positive and gram-negative species, supporting use in mild to moderate infection and in surgical prophylaxis. The extended dosing interval is of practical value in outpatient parenteral antibiotic therapy. The molecule is C18H18N6O8S3 with a mass near 542.6 g/mol, approved and developed through the final phase.

A second-generation cephalosporin antibiotic with a prolonged half-life that allows for once-daily intramuscular dosing, used for mild to moderate infections and surgical prophylaxis. It is effective against many gram-positive and gram-negative bacteria. Its extended dosing interval offers practical convenience in outpatient parenteral antibiotic therapy.

Молекулярная масса

542,6000 g/mol

LogP

-1,90

TPSA

264,00 Ų

Правило пяти Липинского

Не соответствует

Терапевтические области

Infectious Disease

Механизм действия

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12

                

                

                
                

                    
InChI

                    
InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H18N6O8S3

                    

                    
                    

                        
HBD / HBA

                        
4 / 13

                    

                    
                    

                        
Вращаемые Связи

                        
9

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
35

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
A second-generation cephalosporin antibiotic with a prolonged half-life that allows for once-daily intramuscular dosing, used for mild to moderate infections and surgical prophylaxis. It is effective against many gram-positive and gram-negative bacteria. Its extended dosing interval offers practical convenience in outpatient parenteral antibiotic therapy.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Cefonicid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1601.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 43594.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.